Search

Prostatakarzinom

• Hochrisiko M0 PCa (im Anschluss an radikale Prostatektomie): 
  • Phase II Studie ADAM: Apalutamid adjuvant vs. Standard of Care

• Neu diagnostiziertes M1 PCa (hormonsensitiv)
  • Phase III Capitello Studie: Capivasertib + Abiraterone Versus Plazebo + Abiraterone beim De Novo mHSPC mit PTEN Verlust
  • Abirateron plus Niraparib versus Abirateron + Plazebo (bei Vorhandensein einer DNA-Reparaturgen-Mutation, wird im Rahmen der Studie getestet)
  • Enzalutamid + Talazoparib versus Enzalutamid + Plazebo (bei Vorhandensein einer DNA-Reparaturgen-Mutation, wird im Rahmen der Studie getestet
  • Abiraterone + Abemaciclib vs. Abiraterone plus Placebo bei Hochrisiko metastasiertem Prostatakarzinom

• mCRPC (noch keine vorherige Behandlung mit neuer hormoneller Therapie
  • HC-1119 (neues Antiandrogen) versus Enzalutamid

• mCRPC (Progress nach Abiraterone/Enzalutamid/Apalutamid/Darolutamid)
  • Cabozantinib + Atezolizumab vs. Abiraterone/Enzalutamid
  • Nivolumab + Docetaxel vs. Placebo + Docetaxel

• mCRPC (Progress nach Docetaxel und Abiraterone/Enzalutamid/Apalutamid/Darolutamid)
  • Tyrosinkinaseinhibitor XL-092 als Monotherapie oder in Kombination mit Atezolizumab

• Neuroendokrines Prostatakarzinom

  • Pembrolizumab + Lenvatinib oder Pembrolizumab + Vibostolimab (Immuntherapie), Alternativ:Pembrolizumab + Platinhaltige Chemotherapie

• Phase II Studie bei Patienten mit progredientem mCRPC nach mindestens einer, maximal 2 Chemotherapien (sonstige Vortherapien (z.B. Zytiga/Enzalutamid/Apalutamid) erlaubt): Ipiliumab plus Nivolumab vs. Ipilimumab vs. Cabazitaxel. 
• Phase III Studie bei Patienten mit progredientem mCRPC und Vortherapie mit Enzalutamid oder Abiraterone (im mCRPC Stadium): Docetaxel +/- Nivolumab
• Phase III Studie bei Patienten mit progredientem mCRPC und Vortherapie mit Zytiga: Enzalutamid plus Pembrolizumab vs. Enzalutamid plus Placebo. 
• Phase II/III Studie für Patienten mit metastasiertem, hormonrefraktären Prostatakarzinom, Progress unter antihormoneller Therapie: Abiraterone/Prednison +/- Abemaciclib (CDK4/6 Cyclin Inhibitor), Phase II, EudraCT Nr. 2016-004276-21
• Phase III Studie für Patienten mit metastasiertem, hormonrefraktären Prostatakarzinom, Progress unter antihormoneller Therapie: Enzalutamid +/- Talazoparib (PARP Inhibitor) 
• Phase III Studie bei Patienten mit progredientem mCRPC und Vortherapie mit Abiraterone, Enzalutamid oder Apalutamid : PARP Inhibitor Rucaparib vs. Enzalutamid/Abiraterone/Docetaxel. Nachweis einer BRCA Mutation notwendig (wird getestetet).
• Biochemisches Rezidiv bei Z.n. Prostatektomie und/oder Radiatio: RhoVac Peptidvakzinierung (zur Verzögerung einer Hormontherapie) Phase 2 (Eudra CT 2019-000951-14)7
• Orales Docetaxel (Modradoc) vs. i.v. Docetaxel bei mCRPC (EudraCT: 2019-00582-21)
• Phase III Studie Propel: Abiraterone + Olaparib vs. Abiraterone + Placebo bei mCRPC (EudraCT 2018-002011-10)
• Kombinationstherapien mit Pembrolizumab beim mCRPC (Keynote 365) EudraCT 2016-002312-41
• Studie mit dem Antiandrogen ODM-201 für Patienten mit nicht-metastasiertem, hormonrefraktären Prostatakarzinom, ARAMIS, Phase III, EudraCT Nr. 2013-003820-36
• Studie mit Xtandi zur Androgendeprivationstherapie beim metastasierten, hormonsensitiven Prostatakarzinom, ARCHES, Phase III, EudraCT Nr. 2015-003869-28
• Phase III Studie bei Patienten mit progredientem mCRPC und Vortherapie mit Enzalutamid oder Abiraterone (im mCRPC Stadium): Docetaxel +/- Pembrolizumab
• Phase III Studie für Patienten mit metastasiertem, hormonrefraktären Prostatakarzinom, Progress unter antihormoneller Therapie: Abirateron +/- Niraparib (PARP Inhibitor) 
• Phase III Studie für Patienten mit mCRPC nach Progress einer Chemotherapie und einer neuen hormonellen Therapie: Olaparib + Pembrolizumab vs. Enzalutamid/Abirateron

Adresse: http://www.studienurologie.de/klinische-studien/therapieansatz-in-klinischen-studien-bei-prostatakrebs/ Treffer-Übereinstimmung: 0,11

Adresse: http://www.studienurologie.de/referenzen/publizierte-poster-der-studienpraxis/ Treffer-Übereinstimmung: 0,04

• DGHO 2017

  LATITUDE, eine Phase III doppelblinde, randomisierte Studie mit Androgen - Deprivationstherapie (ADT) und Abirateron Acetat (AA) plus Prednison (P) oder Plazebos (PBOs) bei Patienten mit neu-diagnostiziertem, metastasierten, Hormon-naiven Hochrisiko-Prostatakarzinom (mHNPC)

  Feyerabend, N. Tran, L. Fein, N. Matsubara, A. Rodriguez-Antolin, B.Y. Alekseev, M. Özgüroğlu, D. Ye, A. Protheroe, P. De Porre, T. Kheoh, Y.C. Park, M.B. Todd, K.N. Chi, K. Fizazi, für die Prüfärzte der LATITUDE

  Plenary Session, Oral Presentation

• ESMO 2017

  Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)

  Stenzl, S. Feyerabend, I. Syndikus, T. Sarosiek, A. Skrzypczyk, H. Kübler, A. Heidenreich, J. Pernicka, R. Cathomas, R. Zdrojowy, C. Grüllich, S. Szymula, U. Klinkhardt, A. Schröder, O. Schönborn-Kellenberger, V. Reus, S. Koch, H. Hong, B. Scheel, and U. Gnad-Vogt

  Abstract

• ASCO 2017

  LATITUDE: A phase 3, double-blind, randomized trial of androgen deprivation therapy with Abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naïve prostate cancer patients

  Karim Fizazi, NamPhuong Tran, Luis Fein, Nobuaki Matsubara, Alfredo Rodriguez-Antolin, Boris Y. Alekseev, Mustafa Özgüroğlu, Dingwei Ye, Susan Feyerabend, Andrew Protheroe, Peter De Porre,¹¹ Thian Kheoh,  Youn C. Park, Mary B. Todd, Kim N. Chi, on behalf of the LATITUDE Investigators

  Plenary Session, Oral Presentation

• ASCO 2017

  Real-world Outcomes in Second-line Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC): The Prostate Cancer Registry

  Simon Chowdhury, Alison J. Birtle, Anders Bjartell, Luis Costa, Susan Feyerabend, Luca Galli, Ewa Kalinka-Warzocha, Gero Kramer, Nicolaas Lumen, Pablo Maroto, Vsevolod B. Matveev, Thomas Paiss, Salvatore Pisconti, Dominique Spaeth, Francisco Gómez Veiga, Laurent Antoni, Edwin Klumper, Robert Wapenaar, Erik van den Berg, Emma Lee

  Poster

• ASCO 2017

  Treatment Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Cardiovascular Disorders or Diabetes: The Prostate Cancer Registry

  Nicolaas Lumen, Simon Chowdhury, Alison J Birtle, Anders Bjartell, Luis Costa, Susan Feyerabend, Luca Galli, Ewa Kalinka-Warzocha, Gero Kramer, Pablo Maroto, Vsevolod B Matveev, Thomas Paiss, Salvatore Pisconti, Dominique Spaeth, Francisco Gómez Veiga, Laurent Antoni,  Edwin Klumper, Robert Wapenaar, Florence Thoret-Bauchet, Emma Lee

  Abstract

• ASCO GU 2017

  Real-world Outcomes in Second-line Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC): The Prostate Cancer Registry

  Simon Chowdhury, Alison J. Birtle, Anders Bjartell, Luis Costa, Susan Feyerabend, Luca Galli, Ewa Kalinka-Warzocha, Gero Kramer, Nicolaas Lumen, Pablo Maroto, Vsevolod B. Matveev, Thomas Paiss, Salvatore Pisconti, Dominique Spaeth, Francisco Gómez Veiga, Laurent Antoni, Edwin Klumper, Robert Wapenaar, Erik van den Berg, Emma Lee

  Poster

• ASCO GU 2017

  Efficacy and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with Abiraterone acetate plus prednisone: A multicenter, single-arm, open-label study

  Johann S. de Bono, Simon Chowdhury, Susan Feyerabend, Tony Elliot, Enrique Grande, Amal Melhem-Bertrandt, Benoit Baron, Mohammad Hirmand, Patrick Werbrouck, Karim, Fizazi

• EAU 2017

  Treatment Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Cardiovascular Disorders or Diabetes: The Prostate Cancer Registry

  Nicolaas Lumen, Simon Chowdhury, Alison J Birtle, Anders Bjartell, Luis Costa, Susan Feyerabend, Luca Galli, Ewa Kalinka-Warzocha, Gero Kramer, Pablo Maroto, Vsevolod B Matveev, Thomas Paiss, Salvatore Pisconti, Dominique Spaeth, Laurent Antoni,  Edwin Klumper, Robert Wapenaar, Florence Thoret-Bauchet, Emma Lee

  Abstract

• ASCO GU 2016

  Efficacy and safety of ENZAalutamide (ENZAA) in patients with progressive metastatic castration-resistant prostate cancer (mCRPC) previously treated with Abiraterone acetate (Abi): a multicenter, single-arm, open-label study

  Johann De Bono, Simon Chowdhury, Susan Feyerabend, Tony Elliott, Enrique Grande Pulido, Amal Melhem-Bertrandt, Benoit Baron, Mohammad Hirmand, Patrick Werbrouck, Karim Fizazi

  Abstract

• EMUC 2016

  Prospective, non-interventional study on the influence of adherence measures on the therapy with Abiraterone acetate (AA) + prednisone/prednisolone (P) in patients with metastatic, castration resistant prostate carcinoma (IMPACT)

  Henrik Suttmann, Susan Feyerabend, Jochen Gleissner, Andreas Huebner, Edmund A. M. Neugebauer, Tim Mathes, Werner Baurecht , Natasha Schuier

  Posteraward

• ESMO 2016

  The Prostate Cancer Registry: Patient Characteristics, Treatments and Preliminary Outcomes From a Large Observational Study of Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  Simon Chowdhury, Alison J. Birtle, Anders Bjartell, Luis Costa, Susan Feyerabend, Luca Galli, Ewa Kalinka-Warzocha, Gero Kramer, Nicolaas Lumen, Pablo Maroto, Vsevolod B. Matveev, Thomas Paiss, Dominique Spaeth, Laurent Antoni, Edwin Klumper,
  Robert Wapenaar and Emma Lee
   
  Poster

• ASCO 2016

  The Prostate Cancer Registry: Do patients with metastatic castration-resistant prostate cancer (mCRPC) differ according to metastatic status at diagnosis?

  Simon Chowdhury, Alison J. Birtle, Anders Bjartell, Luis Costa, Susan Feyerabend, Luca Galli, Ewa Kalinka-Warzocha, Gero Kramer, Nicolaas Lumen, Pablo Maroto, Vsevolod B. Matveev, Thomas Paiss, Dominique Spaeth, Laurent Antoni, Edwin Klumper, Robert Wapenaar and Emma Lee

  Poster

• ASCO 2016

  The Prostate Cancer Registry: Do patients with metastatic castration-resistant prostate cancer (mCRPC) differ according to metastatic status at diagnosis?

  Simon Chowdhury, Alison J. Birtle,Anders Bjartell,Luis Costa,Susan Feyerabend,Luca Galli,Ewa Kalinka-Warzocha, Gero Kramer, Nicolaas Lumen, Pablo Maroto,Vsevolod B. Matveev,Thomas Paiss,Dominique Spaeth,Laurent Antoni,Edwin Klumper,Robert Wapenaar and Emma Lee
  Center, Moscow, Russia;
  
  Abstract

• ASCO GU2016

  A Randomized Trial of Abiraterone Acetate Administered With 1 of 4 Glucocorticoid Regimens in Metastatic Castration-Resistant Prostate Cancer

  Gerhardt Attard, Axel S. Merseburger, Cora N. Sternberg, Linda Cerbone, Federica Recine, Robert Jones, Susan Feyerabend, Alfredo Berruti, Steven Joniau,Peter Schatteman, Lajos Géczi, Peter Tenke, Patrick Werbrouck, Florence Lefresne, Florence Nave Shelby, Marjolein Lahaye, Corinna Pick and Bertrand Tombal
  Poster

  Poster

• JUA, 25 April 2016, Sendai, Japan

  A Randomised Trial of Abiraterone Acetate Administered With 1 of 4 Glucocorticoid Regimens in Metastatic Castration-Resistant

  Bertrand Tombal, Axel S. Merseburger, Cora N. Sternberg, Linda Cerbone, Federica Recine, Robert Jones, Susan Feyerabend, Alfredo Berruti, Steven Joniau, Peter Schatteman, Lajos Géczi, Péter Tenke, Patrick Werbrouck, Florence Lefresne, Florence Nave Shelby, Marjolein Lahaye, Corinna Pick, Gerhardt Attard
  Presentation

  Poster

• EAU 2016

  A Randomised Trial of Abiraterone Acetate Administered With 1 of 4 Glucocorticoid Regimens in Metastatic Castration-Resistant

  Axel S. Merseburger, Bertrand Tombal, Cora N. Sternberg, Linda Cerbone, Federica Recine, Robert Jones, Susan Feyerabend, Alfredo Berruti, Steven Joniau, Peter Schatteman, Lajos Géczi, Péter Tenke, Patrick Werbrouck, Florence Lefresne, Florence Nave Shelby, Marjolein Lahaye, Corinna Pick, Gerhardt Attard

  Presentation

• EAU 2016

  Prospective, non-interventional study on the influence of adherence measures on the therapy with Abiraterone acetate (AA) + prednisone/prednisolone (P) in patients with metastatic, castration resistant prostate carcinoma (IMPACT)

  Henrik Suttmann, Susan Feyerabend, Jochen Gleissner, Andreas Huebner, Edmund A. M. Neugebauer, Tim Mathes, Werner Baurecht, Natasha Schuier
   

  Abstract

• EAU 2016

  The Prostate Cancer Registry: Second Analysis of a Prospective, International, Observational Study in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  Nicolaas Lumen, Simon Chowdhury, Alison J Birtle, Anders Bjartell, Luis Costa, Susan Feyerabend, Luca Galli, Ewa Kalinka-Warzocha, Pablo Maroto, Vsevolod B Matveev, Thomas Paiss, Dominique Spaeth, Edwin Klumper, Torunn Thingstad, Marieke Buitenhuis  Robert Wapenaar, Emma Lee

  Abstract

• ESMO 2016

  SURECAP: Survey and Evaluation of Castration Resistant Prostate Cancer (CRPC)

  Axel S. Merseburger, Lenka Kellermann, Andreas Janitzky, Martin Hatzinger, Susan Feyerabend, Christiana Lütter, Katrin Krützfeldt, Marina Akkermann, Natasha Schuier

  Abstract

• GU ASCO 2016

  A Randomized Study of Abiraterone Acetate (AA) Administered With 4 Glucocorticoid (GC) Treatment Regimens in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients (pts)

  Gerhardt Attard, Bertrand Tombal, Axel Merseburger, Cora N. Sternberg, Linda Cerbone, Federica Recine, Robert Jones, Susan Feyerabend, Alfredo Berruti, Steven Joniau, Peter Schatteman, Lajos Géczi, Peter Tenke, Patrick Werbrouck, Florence Nave, Marjolein Lahaye, Corinna Pick and Florence Lefresne

  Poster

• ISPOR 2015

  The Prostate Cancer Registry: analysis of medical resource Utilisation (MRU) in an International, Prospective, Observational Study of Men with Metastatic Castration -Resistant Prostate Cancer (mCRPC)

  Simon Chowdhury, Alison J Birtle, Anders Bjartell, Luis Costa, Susan Feyerabend, Luca Galli, Nicolaa Ewa Kalinka-Warzocha, Pablo Maroto, Vsevolod B. Matveev, Thomas Paiss, Dominique Spaeth, Lindsay Dearden, Edwin Klumper, Torunn Thingstad, Robert Wapenaar, and Emma Lee

  Poster

• EAU 2015

  A Randomized Trial of Abiraterone Acetate (AA) Administered With 1 of 4 Glucocorticoid (GC) Regimens in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients (pts)

  Axel S. Merseburger, Bertrand Tombal, Cora N. Sternberg, Linda Cerbone, Federica Recine, Robert Jones, Susan Feyerabend, Alfredo Berruti, Steven Joniau, Peter Schatteman, Lajos Géczi, Peter Tenke, Patrick Werbrouck, Florence Lefresne, Florence Nave Shelby, Marjolein Lahaye, Corinna Pick, Gerhardt Attard

  Presentation

• ASCO 2015

  Phase 3 SYNERGY trial: doce +/- custirsen and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and poor prognosis

  K.N. Chi, C. Higano, J. Reeves, S. Feyerabend, G. Gravis, J.-M. Ferrero, C. Jacobs, O. Barnett-Griness, A. Pande, J.S. De Bono

  Poster

• ESMO 2015

  Phase 3 SYNERGY trial: doce +/- custirsen and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and poor prognosis

  K.N. Chi, C. Higano, J. Reeves, S. Feyerabend, G. Gravis, J.-M. Ferrero, C. Jacobs, O. Barnett-Griness, A. Pande, J.S. De Bono

  Presentation

• ASCO GU 2015

  Final Analysis of COMET-1: Cabozantinib versus Prednisone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) in Patients Previously Treated With Doce and Abiraterone and/or Enzalutamide

  Smith MR, de Bono JS, Sternberg CN, Le Moulec S, Oudard S, De Giorgi U, Krainer M, Bergman AM, Hölzer W, De Wit R, Bögemann M, Saad F, Cruciani G, Thiery-Vuillemin A, Feyerabend S, Miller K, Ramies DA, Hessel C, Weitzman AL, and Fizazi K

  Poster

• ECC 2015

  The Prostate Cancer Registry: First Results from an International, Prospective, Observational Study of Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  Simon Chowdhury, Alison J Birtle, Anders Bjartell, Luis Costa, Susan Feyerabend, Luca Galli, Nicolaas Lumen, Ewa Kalinka-Warzocha, Pablo Maroto, Vsevolod B Matveev, Thomas Paiss, Dominique Spaeth, Edwin Klumper, Torunn Thingstad, Robert Wapenaar and Emma Lee

  Poster

• ESMO 2014

  A randomized phase 3 study comparing first-line doce/prednisone (DP) to DP plus custirsen in men with metastatic castration-resistant prostate cancer (mCRPC)
  
  K.N. Chi, C. Higano, J. Reeves, S. Feyerabend, G. Gravis, J.-M. Ferrero, C. Jacobs, O. Barnett-Griness, A. Pande, J.S. De Bono

  Abstract

Adresse: http://www.studienurologie.de/referenzen/abstracts-und-praesentationen-von-studienergebnissen/ Treffer-Übereinstimmung: 0,01

Adresse: http://www.studienurologie.de/klinische-studien/aktuelles/ Treffer-Übereinstimmung: 0,00